Amphastar Pharmaceuticals Statistics
Amphastar Pharmaceuticals (29A) Stock Statistics & Valuation Metrics
Total Valuation
Amphastar Pharmaceuticals has a market cap or net worth of EUR 1.12B. The enterprise value is EUR 1.58B.
- Market Cap
- EUR 1.12B
- Enterprise Value
- EUR 1.58B
Share Statistics
Amphastar Pharmaceuticals has 42,652,153 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 42,652,153
- Owned by Insiders
- 28.11%
- Owned by Institutions
- 50.77%
Financial Efficiency
Amphastar Pharmaceuticals’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 7.52%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 7.52%
- Return on Capital Employed (ROCE)
- 0.10
- Revenue Per Employee
- 364.32K
- Profits Per Employee
- 49.64K
- Employee Count
- 1,976
- Asset Turnover
- 0.44
- Inventory Turnover
- 2.06
Valuation Ratios
The current PE Ratio of Amphastar Pharmaceuticals is 12.71. Amphastar Pharmaceuticals’s PEG ratio is -2.99.
- PE Ratio
- 12.71
- PS Ratio
- 1.64
- PB Ratio
- 1.50
- Price to FCF
- 8.77
- Price to Operating Cash Flow
- 6.95
- PEG Ratio
- -2.99
Income Statement
In the last 12 months, Amphastar Pharmaceuticals had revenue of 719.89M and earned 98.09M in profits. Earnings per share was 2.10.
- Revenue
- 719.89M
- Gross Profit
- 356.06M
- Operating Income
- 140.40M
- Pretax Income
- 123.62M
- Net Income
- 98.09M
- EBITDA
- 212.31M
- Earnings Per Share (EPS)
- 2.10
Cash Flow
In the last 12 months, operating cash flow was 175.33M and capital expenditures -36.31M, giving a free cash flow of 139.01M billion.
- Operating Cash Flow
- 175.33M
- Free Cash Flow
- 139.01M
- Free Cash Flow per Share
- 3.26
Dividends & Yields
Amphastar Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 11.42%
- Earnings Yield
- 8.14%
Stock Price Statistics
- Beta
- 0.58
- 52-Week Price Change
- 26.23%
- 50-Day Moving Average
- 21.96
- 200-Day Moving Average
- 18.71
- Relative Strength Index (RSI)
- 68.32
- Average Volume (3m)
- 61
Important Dates
Amphastar Pharmaceuticals upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Amphastar Pharmaceuticals as a current ratio of 4.02, with Debt / Equity ratio of 83.16%
- Current Ratio
- 4.02
- Quick Ratio
- 2.90
- Debt to Market Cap
- 0.49
- Net Debt to EBITDA
- 2.29
- Interest Coverage Ratio
- 5.51
Taxes
In the past 12 months, Amphastar Pharmaceuticals has paid 25.53M in taxes.
- Income Tax
- 25.53M
- Effective Tax Rate
- 0.21
Enterprise Valuation
Amphastar Pharmaceuticals EV to EBITDA ratio is 7.72, with an EV/FCF ratio of 12.26.
- EV to Sales
- 2.29
- EV to EBITDA
- 7.72
- EV to Free Cash Flow
- 12.26
- EV to Operating Cash Flow
- 9.72
Balance Sheet
Amphastar Pharmaceuticals has EUR 230.63M in cash and marketable securities with EUR 691.69M in debt, giving a net cash position of -EUR 461.06M billion.
- Cash & Marketable Securities
- EUR 230.63M
- Total Debt
- EUR 691.69M
- Net Cash
- -EUR 461.06M
- Net Cash Per Share
- -EUR 10.81
- Tangible Book Value Per Share
- EUR 4.09
Margins
Gross margin is 46.81%, with operating margin of 18.74%, and net profit margin of 13.27%.
- Gross Margin
- 46.81%
- Operating Margin
- 18.74%
- Pretax Margin
- 17.37%
- Net Profit Margin
- 13.27%
- EBITDA Margin
- 29.59%
- EBIT Margin
- 20.94%
Analyst Forecast
The average price target for Amphastar Pharmaceuticals is EUR 22.52, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 22.52
- Price Target Upside
- 12.19% Downside
- Analyst Consensus
- Neutral
- Analyst Count
- 4
- Revenue Growth Forecast
- -1.94%
- EPS Growth Forecast
- -9.38%
Scores
- Smart Score
- 3
- AI Score
- ―
